The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the ...

Changes in the key antigenic regions of H3N2 viruses suggest that the upcoming flu season may require closer attention to ...

Researchers have shown that glioblastoma can take over the skull marrow to dissolve bone and feed its own growth, suggesting ...

Higher consumption of high-fat cheese and cream is associated with a lower risk for dementia, whereas low-fat dairy shows no ...

Data from a new mouse model may help advance therapeutic development in celiac disease, including improved TG2 inhibitors and ...

The ban will not improve safety on social media and will violate children’s rights to access and participation, according to ...

Adding pirfenidone to mycophenolate mofetil shows no significant improvement in lung function compared with mycophenolate ...

The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also ...

Virtual primary care visits were associated with a 49% higher risk for emergency department (ED) visits in children aged 3 ...

The ultrasound-guided attenuation parameter technology can retain diagnostic accuracy for hepatic steatosis irrespective of ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

A UK-led systematic review reports high rates of sexual dysfunction in individuals with axial spondyloarthritis, highlighting ...